

glucagon-like peptide 1 or gastric inhibitory polypeptide in humans. *Am J Physiol Endocrinol Metab*, 293(3), E849-56.

- Morimoto, K., Morisaka, K., & Kamada, A. (1985). Enhancement of nasal absorption of insulin and calcitonin using polyacrylic acid gel. *Journal Of Pharmacy And Pharmacology*, 37(2), 134-136.
- Morishita, M., & Peppas, N. (2006). Is the oral route possible for peptide and protein drug delivery?. *Drug Discovery Today*, 11(19-20), 905-910.
- Morishita, M., Goto, T., Nakamura, K., Lowman, A.M., Takayama, K., & peppas, N.A. (2006). Novel oral insulin delivery systems based on complexation polymer hydrogels: single and multiple administration studies in type 1 and 2 diabetic rats. *J.Control Release*, 110(2006), 587-594.
- Moupti, A., Weingarten, C., Puisieux, F., Luong, T.T., & Durand, G. (1980). Hypoglycemia after liposomized insulin in the rat. *Pediatr. Res*, 14(1980), 174-182.
- Muheem, A., Shakeel, F., Jahangir, M., Anwar, M., Mallick, N., Jain, G., Wasri, M.H., & Ahmed, F.J. (2014). A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives. *Saudi Pharmaceutical Journal*, 22(5), 1-16.
- Mukhopadhyay, P., Sarkar, K., Chakraborty, M., Bhattacharya, S., Mishra, R., & Kundu, PP. (2013). Oral insulin delivery by self-assembled chitosan NPs: In vitro and in vivo studies in diabetic animal model, *Materials Science and Engineering C*, (33):376-382.
- Muranishi S. (1990). Absorption enhancers. *Crit Rev.Ther,Drug Carrier SysL*, 7(1), 1-33.